Sotrovimab has shown reduced neutralization activity in vitro against the Omicron BA.2 variant. As of May 2022, 70% of samples tested in PEI were the BA.2 variant.

These recommendations are largely based on clinical trials evaluating treatment of outpatients with mild COVID-19 illness at high-risk of severe disease

• Recommended anti-SARS-CoV-2 mAbs have shown to reduce the rates of hospitalization and/or death from any cause in unvaccinated outpatients at high-risk of severe disease
• Efficacy in a vaccinated population is not known – clinical trials were either completed at a time when COVID-19 vaccination was not widely available or vaccinated patients were intentionally excluded
• Click here to access the clinical trial on sotrovimab
• Click here to access the clinical trial on casirivimab/imdevimab